

References

This is the reference list for the ACE Clinical Guideline "Management of chronic coronary syndrome".

1. Shu T, Tang M, He B, et al. Assessing global, regional, and national time trends and associated risk factors of the mortality in ischemic heart disease through global burden of disease 2019 study: population-based study. *JMIR Public Health Surveill.* 2024;10:e46821.
2. HealthHub (Singapore). Top 10 reasons for hospitalisation in Singapore (2019-2021). Available from: <https://www.healthhub.sg/a-z/health-statistics/top-10-conditions-of-hospitalisation> [Accessed 23 March 2025].
3. MOH (Singapore). Principal causes of death. Ministry of Health (MOH), Singapore; 2024. Available from: <https://www.moh.gov.sg/others/resources-and-statistics/principal-causes-of-death> [Accessed 23 March 2025].
4. Tušek-Bunc K, Petek D. Comorbidities and characteristics of coronary heart disease patients: their impact on health-related quality of life. *Health and Quality of Life Outcomes.* 2016;14(1):159.
5. Ministry of Health Singapore. Identifying current practices and challenges in ischemic heart disease (IHD) management in primary care. 2024. Unpublished.
6. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 45(36):3415-3537.
7. Ueng KC, Chiang CE, Chao TH, et al. 2023 guidelines of the Taiwan Society of Cardiology on the diagnosis and management of chronic coronary syndrome. *Acta Cardiol Sin.* 2023;39(1):4-96.
8. Patel PP, Fanaroff AC. Optimal medical therapy for chronic coronary disease in 2024: focus on antithrombotic therapy. *Med Clin North Am.* 2024;108(3):489-507.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ.* 2002;324(7329):71-86.
10. Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. *Eur Heart J.* 2024;45(27):2362-2376.
11. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. *Circulation.* 2023;148(9):e9-e119.
12. Liu D, Xu WP, Xu H, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis. *Front Cardiovasc Med.* 2023;10:1265983.
13. O'Riordan JM, Margey RJ, Blake G, et al. Antiplatelet agents in the perioperative period. *Arch Surg.* 2009;144(1):69-76.
14. Thim T, Johansen MB, Chisholm GE, et al. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. *BMC Cardiovasc Disord.* 2014;14:100.

15. Dean L, Kane M. Clopidogrel therapy and CYP2C19 genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. *Medical Genetics Summaries* [Internet]: National Center for Biotechnology Information (US); 2022.
16. Sandhu A, Valle J, Maddox TM. Dual anti-platelet therapy in stable ischemic heart disease: striking a delicate balance: American College of Cardiology; 2015. Available from: <https://www.acc.org/latest-in-cardiology/articles/2015/10/08/09/50/dual-anti-platelet-therapy-in-stable-ischemic-heart-disease> [Accessed 23 March 2025].
17. Virk HU, Escobar J, Rodriguez M, et al. Dual antiplatelet therapy: a concise review for clinicians. *Life* [Internet]. 2023;13(7):1580.
18. O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y(12) inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. *Circulation*. 2020;142(6):538-545.
19. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41(3):407-477.
20. Giubilato S, Lucà F, Abrignani MG, et al. Management of residual risk in chronic coronary syndromes. clinical pathways for a quality-based secondary prevention. *J Clin Med*. 2023; 12(18):5989.
21. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease. *Circulation*. 2015;131(19):e435-e470.
22. Chiang CE, Hung CL, Wu YW, et al. 2023 consensus of Taiwan Society of Cardiology on the pharmacological treatment of chronic heart failure. *Acta Cardiol Sin*. 2023;39(3):361-390.
23. Dancy L, O'Gallagher K, Milton P, et al. New NICE guidelines for the management of stable angina. *Br J Gen Pract*. 2018;68(669):202-203.
24. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the secondary prevention and rehabilitation section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol*. 2021;28(5):460-495.
25. Anderson L, Brown JP, Clark AM, et al. Patient education in the management of coronary heart disease. *Cochrane Database Syst Rev*. 2017;6(6):CD008895.
26. Patterson R, McNamara E, Tainio M, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. *Eur J Epidemiol*. 2018;33(9):811-829.
27. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med*. 2004;116(10):682-692.
28. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med*. 2020;54(24):1451-1462.
29. Ribeiro F, Oliveira NL, Silva G, et al. Exercise-based cardiac rehabilitation increases daily physical activity of patients following myocardial infarction: subanalysis of two randomised controlled trials. *Physiotherapy*. 2017;103(1):59-65.

30. Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev.* 2016;2016(1):CD001800.
31. Duncan MS, Freiberg MS, Greevy Jr RA, et al. Association of smoking cessation with subsequent risk of cardiovascular disease. *JAMA.* 2019;322(7):642-650.
32. Ding N, Sang Y, Chen J, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. *J Am Coll Cardiol.* 2019;74(4):498-507.
33. Tonstad S, Svendsen M. Premature coronary heart disease, cigarette smoking, and the metabolic syndrome. *Am J Cardiol.* 2005;96(12):1681-1685.
34. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA.* 2003;290(1):86-97.
35. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. *Cochrane Database Syst Rev.* 2013;2013(5):CD000165.
36. Martínez-González MA, Gea A, Ruiz-Canela M. The mediterranean diet and cardiovascular health. *Circ Res.* 2019;124(5):779-798.
37. Fung TT, Chiuve SE, McCullough ML, et al. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. *Arch Intern Med.* 2008;168(7):713-720.
38. Lee YQ, Whitton C, Neelakantan N, et al. Dietary patterns and predicted 10-year cardiovascular disease risk in a multiethnic Asian population. *Nutr Metab Cardiovasc Dis.* 2022;32(9):2093-2104.
39. Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. *JAMA Netw Open.* 2022;5(3):e223849